Well-defined polyglutamates as carriers for the treatment of neurodegenerative diseases

2015

Alzheimer’s disease (AD) is a neurodegenerative multiple process of the central nervous system, which currently represents the most common cost of Dementia. The already high incidence of AD is predicted to dramatically increase over the years. In fact, the experts claim that it will become a global epidemy by 2050. Consequently, direct and indirect costs related to AD are doomed to dramatically increase. For instance, only in America, AD related burden will overcome the trillion of dollars by 2050. Moreover, available medication (Exelon®, Namenda®, Aricept®, and Razadyne®) produce moderate symptomatic benefits, but do not stop disease progression. Hence, AD, among other neurodegenerative di…